| World Journal of Oncology, ISSN 1920-4531 print, 1920-454X online, Open Access |
| Article copyright, the authors; Journal compilation copyright, World J Oncol and Elmer Press Inc |
| Journal website https://wjon.elmerpub.com |
Letter to the Editor
Volume 16, Number 2, April 2025, pages 235-238
CD19 Expression in B-Cell Lymphomas and Clinical Considerations in the Evolving Landscape of CD19-Targeted Therapy
Table
| Number (%) | |
|---|---|
| Patients with B-cell non-Hodgkin lymphoma | 288 |
| Diffuse large B-cell lymphoma | 143 (49.7%) |
| Follicular lymphoma | 38 (13.2%) |
| Marginal zone lymphoma | 22 (7.6%) |
| High-grade B-cell lymphoma | 19 (6.6%) |
| Mantle cell lymphoma | 12 (4.2%) |
| Other | 54 (18.7%) |
| Patients with diagnostic biopsy results available | 228 (79.2%) |
| CD19 expression on diagnostic biopsy | 92 |
| CD19 positive | 88 (95.6%) |
| CD19 dim | 1 (1.1%) |
| CD19 negative | 3 (3.3%) |
| Patients with relapsed or refractory disease | 109 (37.8%) |
| Number of relapses across all patients | 155 |
| Relapses with biopsy performed | 75 |
| CD19 expression on relapse biopsy | 35 |
| CD19 positive | 34 (97.1%) |
| CD19 dim | 0 (0%) |
| CD19 negative | 1 (2.9%) |